ANA NLP Poster

October 17, 2016 Kerry Rowe

ana-2016-poster-final

Post navigation

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.
XBRL 30 June 2020 filed with the SEC
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

ANA NLP Poster

Related Posts

Alterity Therapeutics talks to Finance News Network

Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting